SummaryBackground. Since 1977 when TACE was introduced for the first time it became a standard treatment for nonresectable HCC without vascular invasion or extrahepatic disease. TACE is also performed for other indications, such as colorectal metastases, cholangiocarcinoma, neuroendocrine tumors and etc. Material/methods. the evaluation of interventional therapy with DEB-TACE of 8 patients each with unrespectable HCC, cholangiocarcinoma, neuroendocrine metastatic carcinoma. A comparison of therapy-associated complications performed. Results. We analyzed results of DEB-TACE performed in our Hospital since 2014. DEB-TACE was technically successful in all patients. A total of 21 DEB-TACE procedure was performed in 8 patients during the 2-year period. Two patients (20%) had five treatments, 1 patient (15%) had four treatments, 4 patients (50%) had two treatments and 1 (15%) had one treatment. Pain, nausea, fever and fatigue were the most common side effects following DEB-TACE, with a frequency of 76%, 33%, 57% and 71% respectively. Conclusions. The current results show DEB-TACE to produce beneficial tumor response and to have exceptionally low complication rates.